dr. powles on fda approval of pembrolizumab plus axitinib in advanced rcc
Published 5 years ago • 235 plays • Length 1:40Download video MP4
Download video MP3
Similar videos
-
2:02
dr. mcgregor on implications of the fda approval of pembrolizumab/axitinib in rcc
-
2:31
axitinib plus pembrolizumab in advanced rcc
-
1:22
copy of dr. mcgregor on implications of the fda approval of pembrolizumab/axitinib in rcc
-
1:34
dr. rini on pembrolizumab plus axitinib in rcc
-
1:17
dr. vaishampayan on axitinib plus pembrolizumab in advanced rcc
-
1:56
dr. cost on pembrolizumab plus axitinib in patients with rcc
-
1:04
dr. rini discusses pembrolizumab plus axitinib in mrcc
-
1:00
pembrolizumab/axitinib and avelumab/axitinib combo for rcc
-
3:30
promising results for axitinib and pembrolizumab in advanced renal cell cancer
-
1:03
dr. rini on managing the toxicity of pembrolizumab plus axitinib in mrcc
-
1:19
dr. rini on the efficacy of axitinib and pembrolizumab in rcc
-
2:16
dr. rini on axitinib for treatment of metastatic renal cell carcinoma
-
1:34
dr. powles on rationale for keynote-426 in mrcc
-
1:33
dr. powles on the impact of immunotherapy in kidney cancer
-
0:38
dr. petrylak on fda approval of pembrolizumab in bladder cancer
-
1:06
exciting potential of pembrolizumab combined with axitinib for kidney cancer
-
1:10
dr. mcdermott on the promise of pembrolizumab in non-clear cell rcc
-
8:50
updated results of a clinical trial evaluating pembrolizumab axitinib for frontline adv rcc
-
2:18
pembrolizumab monotherapy and pembro-axitinib for rcc